Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KLK7 | P49862 | 2/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15253875 | 0.93 | KLK7 (0.60) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL15966718 | 0.92 | FOLH1 (0.62) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL9051618 | 0.92 | FOLH1 (0.62) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL2334319 | 0.91 | MAPT (0.68) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL699636 | 0.91 | FOLH1 (0.65) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL2467817 | 0.91 | FOLH1 (0.65) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL3210903 | 0.91 | MAPT (0.68) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL1491720 | 0.91 | FOLH1 (0.65) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL2334326 | 0.91 | MAPT (0.68) | FOLH1MAPTKLK7KLK5SIRT2 | |
| SCHEMBL5328141 | 0.90 | SIRT2 (0.66) | FOLH1MAPTKLK7KLK5SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. | 2013-09-19 | — | — | US | disclosed |
| EP-2544702-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112441-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | SPPL2B, ENGASE, PEPD | FOLH1 622/4885MAPT 4483/4885KLK7 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.